Literature DB >> 11046024

Stimulatory function of gp49A, a murine Ig-like receptor, in rat basophilic leukemia cells.

K H Lee1, M Ono, M Inui, T Yuasa, T Takai.   

Abstract

Murine gp49, a 49-kDa type I transmembrane glycoprotein, is a member of the Ig-like receptors expressed on the surface of cells involved in natural immunity such as mast cells, NK cells, and macrophages. The two major subtypes, gp49A and gp49B, are encoded by two different genes adjacent to each other. gp49B contains an immunoreceptor tyrosine-based inhibitory motif in its cytoplasmic region and is known to function as an inhibitory molecule. In contrast, gp49A does not harbor any specific motif for signal transduction, nor has its physiological role been determined. Here we report on the stimulatory nature of gp49A by analyzing biochemical characteristics of chimeric molecules consisting of an ectodomain of Fc receptor and a C-terminal half of gp49A, namely the pretransmembrane, transmembrane, and cytoplasmic portions, expressed on the rat basophilic leukemia mast cell line. Cross-linking of the chimeric receptors evoked cytoplasmic calcium mobilization, PGD(2) release, and transcription of IL-3 and IL-4 genes, but did not elicit degranulation of the cells. The chimeric molecule could be expressed as a singlet and a homodimeric form on the cell surface. A pretransmembrane cysteine residue of gp49A was necessary for dimer formation. Dimerization was be necessary for their incorporation into glycolipid-enriched membrane fraction (GEM) upon cross-linking stimuli. The calcium mobilization response was inhibited by treatment of cells with methyl-beta-cyclodextrin, an inhibitor of GEM formation. Together with these results, it was strongly suggested that gp49A could be expressed as a homodimer and elicit activation signals that lead to calcium mobilization, eicosanoid production, and cytokine gene transcription through its incorporation into GEM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046024     DOI: 10.4049/jimmunol.165.9.4970

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Molecular cloning of LILRC1 and LILRC2 in the mouse and the rat, two novel immunoglobulin-like receptors encoded by the leukocyte receptor gene complex.

Authors:  Sigurd Erik Hoelsbrekken; Sigbjørn Fossum; Erik Dissen
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

3.  CXCR3 expression defines a novel subset of innate CD8+ T cells that enhance immunity against bacterial infection and cancer upon stimulation with IL-15.

Authors:  Steve Oghumu; Cesar A Terrazas; Sanjay Varikuti; Jennifer Kimble; Stephen Vadia; Lianbo Yu; Stephanie Seveau; Abhay R Satoskar
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

4.  Identification of the mouse killer immunoglobulin-like receptor-like (Kirl) gene family mapping to chromosome X.

Authors:  Alice Y Welch; Masanori Kasahara; Lisa M Spain
Journal:  Immunogenetics       Date:  2003-02-04       Impact factor: 2.846

5.  Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia.

Authors:  Niklas Feldhahn; Anna Arutyunyan; Sonia Stoddart; Bin Zhang; Sabine Schmidhuber; Sun-Ju Yi; Yong-Mi Kim; John Groffen; Nora Heisterkamp
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

6.  High-Throughput Sequencing and Co-Expression Network Analysis of lncRNAs and mRNAs in Early Brain Injury Following Experimental Subarachnoid Haemorrhage.

Authors:  Jianhua Peng; Yue Wu; Xiaocui Tian; Jinwei Pang; Li Kuai; Fang Cao; Xinghu Qin; Jianjun Zhong; Xinshen Li; Yong Li; Xiaochuan Sun; Ligang Chen; Yong Jiang
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

7.  Genomic expression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder.

Authors:  Md Suhail Alam; Michelle Getz; Innocent Safeukui; Sue Yi; Pamela Tamez; Jenny Shin; Peter Velázquez; Kasturi Haldar
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

8.  Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

Authors:  S T Philips; Z L Hildenbrand; K I Oravecz-Wilson; S B Foley; V E Mgbemena; T S Ross
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.